Albutrepenonacog Alfa

A recombinant fusion protein that links clotting factor IX with albumin to extend its activity in the blood, used to prevent and treat bleeding in people with hemophilia B who lack sufficient factor IX. The albumin linkage significantly extends the half-life of the clotting factor, allowing less frequent infusions compared to standard factor IX products.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Albutrepenonacog Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.